Clinical trials: Cancer: Solid Tumors
Advanced Solid Tumors
Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.
- Trial name
- NCT00750425
- Testing
- cediranib (RECENTIN TM, AZD2171)
- Where
- 5 sites in Canada, Denmark
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer, Solid Tumor
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and cohort expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics characteristics or preliminary efficacy and antitumor activity in…
- Trial name
- NCT06612840
- Testing
- GNC-077
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion
Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors
This was an open-label, multicenter, nonrandomized Phase 1 and 2 clinical trial evaluating various combinations of surzebiclimab (BGB-A425) and/or alcestobart (LBL-007) with tislelizumab.
- Conditions
- Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in, HNSCC for Phase 2 Dose Expansion, NSCLC for Phase 2 Dose Expansion
- Trial name
- NCT03744468
- Testing
- Surzebiclimab, Tislelizumab, Alcestobart
- Where
- 40 sites in United States, Australia and 4 more
- Volunteers
- 147 people
- Sponsor
- BeiGene
Advanced Solid Tumor
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Phase 1, single-arm, open-label, dose escalating and expansion clinical trial to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of Lurbinectedin (PM01183) for injection in patients with advanced solid…
- Trial name
- NCT04638491
- Testing
- Lurbinectedin for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Luye Pharma Group Ltd.
Solid Malignancies
Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase
This Phase 1, open label, single centre, non-randomised study in patients with advanced solid malignancies consists of two parts: 1.
- Trial name
- 14C (NCT02640755)
- Testing
- [14C]AZD2014, Multiple dose AZD2014, Fulvestrant
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Solid Tumors
Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors
This study will evaluate the safety/tolerability, pharmacokinetics and efficacy of MHB088C in participants with advanced or metastatic solid tumors.
- Trial name
- NCT05652855
- Testing
- MHB088C for Injection
- Where
- 3 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Minghui Pharmaceutical Pty Ltd
Pediatric Oncology
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in…
- Trial name
- NCT02085148
- Testing
- Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Advanced Solid Tumor
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Open-label, two parallel arm, multicenter, Phase 1 dose-escalation study to evaluate the safety and tolerability of OMTX705, both as monotherapy or in combination with pembrolizumab (Part 1) or tislelizumab (Part 2) in the…
- Trial name
- NCT05547321
- Testing
- OMTX705, Pembrolizumab, Tislelizumab (BGB-A317)
- Where
- 9 sites in United States, Spain
- Volunteers
- 150 people
- Sponsor
- Oncomatryx Biopharma S.L.
Advanced or Metastatic Solid Tumors
Phase I Clinical Study of Metatinib Tromethamine Tablet
Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of daily oral administration of metatinib tromethamine in subjects with solid tumors; Investigate the influence of food on pharmacokinetic…
- Trial name
- NCT02004548
- Testing
- Metatinib Tromethamine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Neoplasms
Dose Finding Study of BI 836880 in Patients With Solid Tumors
This is a Phase I, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously. The eligible patient population will be patients with advanced solid tumours.
- Trial name
- NCT02674152
- Testing
- BI 836880
- Where
- 3 sites in France, Germany
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Cancer
Study of PBF-999 in Solid Tumour Advanced Cancer
Multicentric phase I (dose escalation plus expansion) clinical trial of PBF-999 in patients with immunotherapy naïve and pretreated solid tumors to evaluate the safety, tolerability and preliminary efficacy of the compound
- Trial name
- NCT03786484
- Testing
- PBF-999
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Palobiofarma SL
Advanced Solid Tumors Cancer
Trial to Study the Safety, Pharmacokinetics and Preliminary Antitumour Activity of ODM-216 in Patients With Cancer
A Phase 1/2, Open-Label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumour Activity of ODM-216 in Participants With Advanced Solid Tumours
- Trial name
- BICIDES (NCT07805252)
- Testing
- ODM-216
- Where
- 7 sites in Spain
- Volunteers
- 195 people
- Sponsor
- Orion Corporation, Orion Pharma
Solid Tumor
A Clinical Study of SHR-4595 Injection in Patients With Advanced Solid Tumors to Evaluate Safety, Tolerability and Pharmacokinetics
The study is being conducted to evaluate the safety and tolerability of SHR-4595 for injection in participants with advanced solid tumors, and to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and…
- Trial name
- NCT07830199
- Testing
- SHR-4595 for Injection
- Where
- 2 sites in China
- Volunteers
- 208 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Malignant Solid Tumor, Advanced Lung Cancer
A Clinical Study of BT02 in Treating Patients With Advanced Lung Cancer
The goal of this clinical trial is to assess whether an investigational treatment is safe and tolerable for patients with advanced lung cancer, and to get a preliminary idea of its effectiveness.
- Conditions
- Advanced Malignant Solid Tumor, Advanced Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT07110363
- Testing
- BT02
- Volunteers
- 58 people
- Sponsor
- Biotroy Therapeutics
Advanced Solid Tumor
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
This study has three parts. Part 1 is a dose-escalation trial, Part 2 is a pharmacokinetic comparison and food effect study, and Part 3 is extended trial of combination of utidelone capsule and capecitabine.
- Trial name
- NCT05700084
- Testing
- Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A)
- Where
- 10 sites in China
- Volunteers
- 84 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies.
- Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-), Metastatic Colorectal Adenocarcinoma
- Trial name
- NCT07897721
- Testing
- PF-08165784, Fulvestrant, Atirmociclib
- Volunteers
- 268 people
- Sponsor
- Pfizer
Solid Tumor, Metastatic Bone Disease
Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease
This study will estimate the total time for the preparation and administration of denosumab and the total time for the preparation and administration of pamidronate.
- Trial name
- NCT02101164
- Testing
- denosumab, pamidronate
- Sponsor
- Amgen
Solid Tumors
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1203 in Advanced Solid Tumors.
This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1203 in participants with advanced solid tumors.
- Trial name
- NCT07876609
- Testing
- BA1203
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Docetaxel, Solid Tumours
A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours
The study will be conducted in patients with solid tumors for whom single-agent docetaxel, in the dose of 75 mg/m2, is a suitable treatment option.
- Conditions
- Docetaxel, Solid Tumours, Bioequivalence
- Trial name
- NCT04889599
- Testing
- BH009 (Docetaxel injection), Docetaxel injection
- Where
- 3 sites in India
- Volunteers
- 46 people
- Sponsor
- Zhuhai Beihai Biotech Co., Ltd
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.